Hyderabad varsity inks MoU with Natco Pharma for research

Published On 2017-03-24 04:39 GMT   |   Update On 2017-03-24 04:39 GMT

Hyderabad : University of Hyderabad (UoH) has signed an MoU with Natco Pharma for carrying out advance research in the areas of discovery of novel drugs and their delivery systems among others.


According to a release issued by the university on Tuesday, the research includes nano formulations of new chemical entities and novel bio technological processes for specific products with potential commercial importance.


Both the parties will promote cooperation in academic exchange, research and development collaborations, training and research in the areas of biotechnology, pharmacology, toxicology, pharmaceutical technology and organisation of national and international conferences, exhibition and similar events in areas of mutual interest, it said.


School of Life Sciences of UoH has been undertaking collaborative research in the areas of drug discovery for the past several years with Natco. The research has resulted in developing one of the molecules to Phase-II clinical trials for the treatment of chronic myeloid leukaemia, it added.


The MoU, signed for a period of five years, will foster the academy industry interactions by utilisation of expertise of the faculty and infrastructural facilities for promoting anti-cancer drug discovery research and development at Natco, it said.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News